Nizatidine, intended for the short-term treatment of duodenal ulcers and benign gastric ulcers, was found to contain the impurity N-nitrosodimethylamine.
The affected lots were distributed to wholesalers, mail order pharmacies and retail pharmacies between June 2017 and August 2018.
Mylan said it hasn’t received any adverse event reports related to the recall.
Read the full news release here.
More articles on pharmacy:
Walgreens secures enterprisewide specialty accreditation
Drug price hike update: Merck, Allergen, Novartis raise prices
Regeneron restructures, cuts at least 15 jobs
